Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitomycin sustained release - UroGen Pharma

Next Previous
Drug Profile

Mitomycin sustained release - UroGen Pharma

Alternative Names: Jelmyto; MITOGEL; Mitomycin 0.18% gel; Mitomycin 0.4% gel; Mitomycin C mixed with TC Gel; Mitomycin C mixed with TC-3 gel; MMC gel; UGN 101; UGN 102; UGN-103; UGN-104; VESIGEL

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TheraCoat
  • Developer UroGen Pharma
  • Class Amines; Antiglaucomas; Antineoplastics; Aza compounds; Aziridines; Carbamates; Cytostatic antibiotics; Eye disorder therapies; Heterocyclic compounds with 4 or more rings; Indoles; Mitomycins; Pyrroles; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Urogenital cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Urogenital cancer
  • Preregistration Bladder cancer

Most Recent Events

  • 03 Apr 2024 UroGen Pharma files a lawsuit against Teva Pharmaceuticals for infringement of patents directed towards pyelocalyceal solution of mitomycin
  • 26 Mar 2024 UroGen Pharma plans a phase III trial for bladder cancer (Intravesicular) in July 2024 (NCT06331299),
  • 14 Mar 2024 UroGen Pharma plans a phase III trial for UGN-104 formulation in low-grade upper tract urothelial carcinoma (LG-UTUC) in 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top